hPAM4-Cide (yttrium Y-90 clivatuzumab tetraxetan) / Gilead  >>  Phase 3
Welcome,         Profile    Billing    Logout  

1 Trials

Remove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
hPAM4-Cide (yttrium Y-90 clivatuzumab tetraxetan) / Gilead
PANCRIT®-1, NCT01956812 / 2013-004516-21: Phase 3 Trial of 90Y-Clivatuzumab Tetraxetan & Gemcitabine vs Placebo & Gemcitabine in Metastatic Pancreatic Cancer

Terminated
3
334
Europe, Canada, US, RoW
IMMU-107, 90Y-clivatuzumab tetraxetan, placebo, normal saline, Gemcitabine, gemcitabine 200 mg/m2
Gilead Sciences
Metastatic Pancreatic Cancer, Pancreatic Cancer
11/16
11/16

Download Options